Recent Advances in Personalized Treatment Strategies in Idiopathic Pulmonary Fibrosis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Boehringer Ingelheim

Idiopathic pulmonary fibrosis (IPF) is a lung disease that results from the formation of scar tissue deep inside the lungs. As the scarring in the lungs progressively gets worse, it makes it difficult for patients to breathe as well as keep adequate levels of oxygen in the bloodstream. IPF typically has a poor prognosis and is difficult to diagnosis early. In recent years, updated guidelines for the management of IPF were published to provide healthcare professionals the best practices in diagnosis and management of IPF. Diagnosis should start with the elicitation of a thorough and extensive medical history that should include review of symptoms or signs suggestive of a systemic disorder, occupational and environmental exposures, use of medications and drugs, and family medical history. Treatment strategies for IPF aim at managing the symptoms and slowing disease progression to best maintain a patient’s quality of life. More recently, therapeutic options for IPF have evolved to include targeted agents that have the ability to individualize treatment for patients. Along with these treatments, the standard of care for IPF includes oxygen supplementation, management of co-morbidities, and lung transplants. Recent clinical trials have identified new treatments for this disease which will lead to the approval of new therapeutic options by the FDA.

Upon completion of this activity, participants will be able to:

  • Examine current guidelines and new clinical evidence to develop a multi-disciplinary approach for patients with idiopathic pulmonary fibrosis (IPF)

  • Explain the best diagnostic approach for IPF, incorporating current guidelines and evolving modalities

  • Analyze the mechanisms of action, efficacy, and safety profiles of current and emerging therapies for IPF

  • Assess appropriate personalized treatment plans with a focus on patient- and disease-related factors unique to IPF

  • Discuss recent advances in the genetics of pulmonary fibrosis pathogenesis and how they can be applied to improve the standard of care

Faculty: Joseph D. Zibrak, MD
Assistant Professor of Medicine
Harvard Medical School
Director, ILD Center
Division of Pulmonology and Critical Care
Beth Israel Deaconess Medical Center


Dr. Zibrak serves on an advisory board for Boehringer Ingelheim and Genentech. He serves as a consultant for Hoffman La Roche. He has received research/grant support from Galapogos. He serves on the speaker's bureau for Boehringer Ingelheim and Genentech. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Boehringer Ingelheim

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue